- Home
- SEAT vs FLGT Comparison
SEAT vs FLGT Comparison
Compare SEAT & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEAT
- FLGT
- Stock Information
- Founded
- SEAT 2001
- FLGT 2011
- Country
- SEAT United States
- FLGT United States
- Employees
- SEAT N/A
- FLGT N/A
- Industry
- SEAT Industrial Machinery/Components
- FLGT Medical Specialities
- Sector
- SEAT Industrials
- FLGT Health Care
- Exchange
- SEAT Nasdaq
- FLGT Nasdaq
- Market Cap
- SEAT 597.1M
- FLGT 683.5M
- IPO Year
- SEAT N/A
- FLGT 2016
- Fundamental
- Price
- SEAT $4.60
- FLGT $18.76
- Analyst Decision
- SEAT Strong Buy
- FLGT Hold
- Analyst Count
- SEAT 10
- FLGT 1
- Target Price
- SEAT $6.73
- FLGT $22.00
- AVG Volume (30 Days)
- SEAT 1.5M
- FLGT 277.7K
- Earning Date
- SEAT 11-07-2024
- FLGT 02-26-2025
- Dividend Yield
- SEAT N/A
- FLGT N/A
- EPS Growth
- SEAT N/A
- FLGT N/A
- EPS
- SEAT N/A
- FLGT N/A
- Revenue
- SEAT $774,076,000.00
- FLGT $277,761,000.00
- Revenue This Year
- SEAT $10.64
- FLGT N/A
- Revenue Next Year
- SEAT $4.21
- FLGT $16.00
- P/E Ratio
- SEAT $27.06
- FLGT N/A
- Revenue Growth
- SEAT 13.91
- FLGT N/A
- 52 Week Low
- SEAT $3.24
- FLGT $16.56
- 52 Week High
- SEAT $6.41
- FLGT $29.30
- Technical
- Relative Strength Index (RSI)
- SEAT 71.67
- FLGT 47.40
- Support Level
- SEAT $4.45
- FLGT $17.77
- Resistance Level
- SEAT $4.78
- FLGT $18.97
- Average True Range (ATR)
- SEAT 0.29
- FLGT 0.68
- MACD
- SEAT 0.14
- FLGT -0.05
- Stochastic Oscillator
- SEAT 88.08
- FLGT 40.41
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.